MENU
+Compare
BIIB
Stock ticker: NASDAQ
AS OF
Jul 21, 12:18 PM (EDT)
Price
$121.19
Change
-$3.80 (-3.04%)
Capitalization
31.34B

BIIB Biogen Forecast, Technical & Fundamental Analysis

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan... Show more

Industry: #Biotechnology
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for BIIB with price predictions
Jul 18, 2025

BIIB in downward trend: price dove below 50-day moving average on July 18, 2025

BIIB moved below its 50-day moving average on July 18, 2025 date and that indicates a change from an upward trend to a downward trend. In of 44 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 16, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on BIIB as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for BIIB turned negative on July 16, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in of 258 cases, the price rose further within the following month. The odds of a continued upward trend are .

BIIB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 138 cases where BIIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BIIB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.110) is normal, around the industry mean (5.632). P/E Ratio (26.955) is within average values for comparable stocks, (48.974). BIIB's Projected Growth (PEG Ratio) (8.807) is slightly higher than the industry average of (3.004). Dividend Yield (0.000) settles around the average of (0.161) among similar stocks. P/S Ratio (3.181) is also within normal values, averaging (3.643).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock worse than average.

View a ticker or compare two or three
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

BIIB is expected to report earnings to rise 32.12% to $3.99 per share on July 31

Biogen BIIB Stock Earnings Reports
Q2'25
Est.
$3.99
Q1'25
Beat
by $0.06
Q4'24
Beat
by $0.03
Q3'24
Beat
by $0.31
Q2'24
Beat
by $1.27
The last earnings report on May 01 showed earnings per share of $3.02, beating the estimate of $2.96. With 144.58K shares outstanding, the current market capitalization sits at 31.34B.
A.I. Advisor
published General Information

General Information

a manufacturer of therapies for people living with neurological, autoimmune and hematologic disorders

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Biotechnology
Address
225 Binney Street
Phone
+1 617 679-2000
Employees
7570
Web
https://www.biogen.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
QTAP42.400.02
+0.05%
Innovator Growth-100 Acltd Ps ETF™ April
PBQQ27.04N/A
N/A
PGIM LADDERED NASDAQ-100 BUFFER 12 ETF
FIAX17.97N/A
N/A
Nicholas Fixed Income Alternative ETF
JGLO65.12-0.07
-0.11%
JPMorgan Global Select Equity ETF
VVR3.70-0.06
-1.60%
Invesco Senior Income Trust

BIIB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AMGN. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AMGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
-2.88%
AMGN - BIIB
57%
Loosely correlated
-1.17%
PFE - BIIB
49%
Loosely correlated
-0.45%
SNY - BIIB
46%
Loosely correlated
-0.68%
MRK - BIIB
45%
Loosely correlated
-1.91%
NVS - BIIB
44%
Loosely correlated
-0.24%
More